• Corbus posted a net loss of USD 35.04 million in Q2 2026, widening from USD 17.66 million a year earlier; loss per share widened to USD 1.81.
• Total operating expenses rose 88.96% to USD 36.19 million, driven by higher clinical development costs including a USD 10 million CRB-701 milestone payment.
• Cash, cash equivalents and investments totaled USD 117.9 million at June 30, 2026, expected to fund operations into 2028.
• FDA cleared the TEMPO-1 registrational study of CRB-701 in second-line oropharyngeal cancer; enrollment is expected to start in September 2026.
• CANYON-1 Phase 1b obesity trial of CRB-913 reached last patient last visit; topline data are slated for September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.